CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

20-560/S019

Trade Name: Fosamax Tablets

Generic Name: alendronate sodium

Sponsor: Merck Research Laboratories

Approval Date: May 28, 1999

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-560/S019

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	X
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-560/S019

APPROVAL LETTER

NDA 20-560/S-019

Merck Research Laboratories
Attention: Michelle Kloss, Ph.D.
Director, Regulatory Affairs
Sumneytown Pike, P.O. Box 4
BLA-20
West Point, PA 19486

MAY 28 1999

Dear Dr. Kloss:

Please refer to your supplemental new drug application dated February 2, 1999, received February 4, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Fosamax (alendronate sodium) Tablets.

We note that this supplement was submitted as a 'Special Supplement - Changes Being Effected' under 21 CFR 314.70(c).

This supplemental new drug application provides for an additional site [redacted] for the packaging of Fosamax Uniblisters (a previously approved blister package), and a categorical exclusion from the requirement to prepare an environmental assessment for the tablets in these blisters. Your submission stated March 1, 1999 as the implementation date for the change.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

5/28/99

Duu-Gong Wu, Ph.D.
Chemistry Team Leader II, DNDC II for the
Division of Metabolic and Endocrine Drug Products,
(HFD-510)
Office of New Drug Chemistry
Center for Drug Evaluation and Research

RH 5/28/99

cc:
Archival NDA 20-560
HFD-510/Div. Files
HFD-510/R.Hedin
HFD-510/Reviewers and Team Leaders
HFD-95/DDMS (with labeling)
HFD-820/DNDC Division Director
DISTRICT OFFICE

Drafted by: RH/May 25, 1999
Initialed by:SMarkofsky/5.25/DWu/5.26/EGalliers/5.27.99
final: RH/5.28.99
filename: N20560AP.L13

APPROVAL (AP)

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-560/S019

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW	1. ORGANIZATION	2. NDA NUMBER
	DMEDP, HFD-510	20-560

3. NAME AND ADDRESS OF APPLICANT	4. SUPPLEMENT NUMBER, DATE
Merck & Co., Inc. Sumneytown Pike, BLA-20 P.O. Box 4 West Point, PA 19486	SCM-019 02-Feb.-1999 User Fee Date: 8-2-99

5. NAME OF DRUG	6. NONPROPRIETARY NAME	8. AMENDMENTS/REPORT, DATE
Fosamax	Alendronate Sodium Tablets	

7. SUPPLEMENT PROVIDES FOR:	
1) An additional site [redacted] for the packaging of Fosamax Uniblisters (a previously approved blister package) 2) A Categorical Exclusion from the requirement to prepare an Environmental Assessment for the tablets in these blisters	

9. PHARMACOLOGICAL CATEGORY	10. HOW DISPENSED	11. RELATED IND/NDA/DMF
Treatment and prevention of Osteoporosis	Prescription	

12. DOSAGE FORM	13. POTENCY
Tablets (oral)	5, 10, & 40 mg tablets

14. CHEMICAL NAME AND STRUCTURE

See Chem. Rev. # 1

15. COMMENTS:

This Changes Being Effective supplement (CBE) provides for an additional packaging site for Merck's previously approved Uniblister cards (Supplement-010), for Fosamax (10mg) tablets, under the provisions of SUPAC-IR (Stand Alone Packaging Operations Site Changes). **(Continued next page)**

16. CONCLUSION AND RECOMMENDATIONS

From a Chemistry point of view, the proposed supplement is acceptable. Issue an approval letter.

17. NAME	REVIEWER SIGNATURE	DATE COMPLETED
Sheldon Markofsky, Ph.D.	Sheldon Markofsky	4-13-99

DISTRIBUTION: ORIGINAL JACKET/CSO/REVIEWER/DIVISION FILE

R/D initialed by: 5/11/99

File name: n20560s.019

1 Page(s) Withheld

1 § 552(b)(4) Trade Secret / Confidential

_____ § 552(b)(4) Draft Labeling

_____ § 552(b)(5) Deliberative Process

Withheld Track Number: Chemistry- 20-560 S019

ESTABLISHMENT EVALUATION REQUEST SUMMARY REPORT

Application: **NDA 20560/019**
Stamp: **04-FEB-1999** Regulatory Due: **04-AUG-1999**
Applicant: **MERCK**
SUMNEYTOWN PIKE BLA20
WEST POINT, PA 19486

Priority: **1P** Org Code: **510**
Action Goal: District Goal: **30-JUN-1999**
Brand Name: **FOSAMAX (ALENDRONATE SODIUM)10+40MG TABS**
Established Name:
Generic Name: **ALENDRONATE SODIUM**
Dosage Form: **TAB (TABLET)**
Strength: **10 MG**

FDA Contacts:			
	D. HEDIN	**(HFD-510)**	**301-827-6392 , Project Manager**
	S. MARKOFSKY	**(HFD-510)**	**301-827-6430 , Review Chemist**
	D. WU	**(HFD-510)**	**301-827-6375 , Team Leader**

Overall Recommendation:

ACCEPTABLE on 22-FEB-1999 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: [redacted]
DMF No:
AADA No:

Profile: **TCM** OAI Status: **NONE**
Last Milestone: **OC RECOMMENDATION**
Milestone Date **22-FEB-1999**
Decision: ***ACCEPTABLE***
Reason: **BASED ON PROFILE**

Responsibilities: [redacted]

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-560/S019

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-560/S-019

FEB 19 1999

Merck Research Laboratories
Sumneytown Pike P.O. Box 4 BLA-20
West Point, PA 19486

Attention: Michelle W. Kloss, Ph.D.
Director, Regulatory Affairs

Dear Dr. Kloss:

We acknowledge receipt of your supplemental application for the following:

Name of Drug:	Fosamax® (Alendronate Sodium Tablets)
NDA Number:	20-560
Supplement Number:	S-019
Date of Supplement:	February 2, 1999
Date of Receipt:	February 4, 1999

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on April 5, 1999, in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Attention: Document Control Room 14B-19
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

Enid Galliers
Chief, Project Management Staff
Division of Metabolic and Endocrine
Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:
Original NDA 20-560/S-019
HFD-510/Div. Files
HFD-510/CSO/R. Hedin

filename: C:\DATA\WPFILES\20560ACK.

SUPPLEMENT ACKNOWLEDGEMENT /CBE

Michelle W. Kloss, Ph.D.
Director
Regulatory Affairs

ORIGINAL

Merck & Co., Inc.
P.O. Box 4, BLA-20
West Point PA 19486-0004
Tel 610 397 2905
Fax 610 397 2516

These copies are OFFICIAL FDA Copies not desk copies.

February 2, 1999



Solomon Sobel, M D., Director
Division of Metabolism and Endocrine Drug Products
HFD-510, Room 14B-04
Office of Drug Evaluation II (CDER)
Food and Drug Administration
9201 Corporate Blvd.
Rockville, Maryland 20850

NDA NO. 20-560 REF NO. 019
NDA SUPPL FOR SCM

NDA 20-560: FOSAMAX™
(Alendronate Sodium Tablets)

SPECIAL SUPPLEMENT – CHANGES BEING EFFECTED

Dear Dr. Sobel:

Pursuant to Section 505(b) of the Food Drug and Cosmetic Act and in accordance with 21 CFR 314.70(c), we submit a supplement to NDA 20-560.

As indicated on the attached Form FDA 356h, this supplemental application provides for changes in the Chemistry Section of the approved New Drug Application for FOSAMAX™.

The purpose of this supplement is to add [redacted] as a packaging site for the FOSAMAX™ UNIBLISTER™. This filing is being submitted in accordance with the provisions of SUPAC-IR involving Stand Alone Packaging Operations Site Changes as stipulated in correspondence from Roger L. Williams, M.D., (FDA) dated February 18, 1997. The following items are included in this submission:

- Address of the [redacted] and the dates of the last GMP inspection conducted by FDA at that facility
- Letter of authorization from [redacted] to refer to their DMF, including certification that the facility is in conformance with cGMPs
- Request for categorical exclusion from the requirements for preparing an environmental assessment
- Commitment to place on stability the [redacted] of FOSAMAX™ packaged in the UNIBLISTER™ at [redacted]

Packaging operations at [redacted] are targeted to begin on March 1, 1999.

In accordance with the Food and Drug Administration Modernization Act of 1997, as indicated in the attached Form 3397, no user fee is required for this supplemental application.

Pursuant to 21 CFR 314.70(a), a complete field copy of this supplement has been submitted to the FDA Philadelphia District Office.

As required by Section 306(k)(1) of the Generic Enforcement Act [21 U.S.C. 335a(k)(1)], we hereby certify that, in connection with this application, Merck & Co., Inc. did not and will not use in any capacity the services of any person debarred under subsections 306(a) or (b) of the Act.

We consider the filing of this Supplemental New Drug Application to be a confidential matter, and request the Food and Drug Administration not to make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc.

Questions concerning this supplemental application should be directed to Michelle W. Kloss, Ph.D. (610/397-2905) or, in my absence, to Larry P. Bell, M.D. (610/397-2310).

Sincerely,

Michelle W. Kloss

Michelle W. Kloss, Ph.D.
Director
Regulatory Affairs

Q/carnal/mk0217/cbe/cbe2_99

Attachments

Federal Express #1

Desk Copy
Mr. Randy Hedin, HFD-510, Room 14B-04 - Federal Express #1

Ms. Debra Pagano
Philadelphia District Office
Food & Drug Administration
U.S. Custom House Room 900
2nd and Chestnut Street
Philadelphia, Pennsylvania 19106-2973 - Federal Express #2

REVIEWS COMPLETED

CSO ACTION:
☐ LETTER ☐ N.A.I. ☐ MEMO

CSO INITIALS DATE

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Form Approved: OMB No. 0910-0297
Expiration Date: 04-30-01

USER FEE COVER SHEET

See Instructions on Reverse Side Before Completing This Form

1. APPLICANT'S NAME AND ADDRESS

Merck & Co., Inc.
Sumneytown Pike, BLA-10
P. O. Box 4
West Point, PA 19486

2. TELEPHONE NUMBER *(Include Area Code)*

(610) 397-2383

3. PRODUCT NAME

Fosamax™

4. DOES THIS APPLICATION REQUIRE CLINICAL DATA FOR APPROVAL? IF YOUR RESPONSE IS "NO" AND THIS IS FOR A SUPPLEMENT, STOP HERE AND SIGN THIS FORM.

IF RESPONSE IS 'YES', CHECK THE APPROPRIATE RESPONSE BELOW:

☐ THE REQUIRED CLINICAL DATA ARE CONTAINED IN THE APPLICATION.

☐ THE REQUIRED CLINICAL DATA ARE SUBMITTED BY REFERENCE TO _____ (APPLICATION NO. CONTAINING THE DATA).

5. USER FEE I.D. NUMBER

6. LICENSE NUMBER / NDA NUMBER

7. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE **EXCLUSIONS**? IF SO, CHECK THE APPLICABLE EXCLUSION.

☐ A LARGE VOLUME PARENTERAL DRUG PRODUCT APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT BEFORE 9/1/92 *(Self Explanatory)*

☐ A 505(b)(2) APPLICATION THAT DOES NOT REQUIRE A FEE *(See item 7, reverse side before checking box.)*

☐ THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 736(a)(1)(E) of the Federal Food, Drug, and Cosmetic Act *(See item 7, reverse side before checking box.)*

☐ THE APPLICATION IS A PEDIATRIC SUPPLEMENT THAT QUALIFIES FOR THE EXCEPTION UNDER SECTION 736(a)(1)(F) of the Federal Food, Drug, and Cosmetic Act *(See item 7, reverse side before checking box.)*

☐ THE APPLICATION IS SUBMITTED BY A STATE OR FEDERAL GOVERNMENT ENTITY FOR A DRUG THAT IS NOT DISTRIBUTED COMMERCIALLY *(Self Explanatory)*

FOR BIOLOGICAL PRODUCTS ONLY

☐ WHOLE BLOOD OR BLOOD COMPONENT FOR TRANSFUSION

☐ A CRUDE ALLERGENIC EXTRACT PRODUCT

☐ AN APPLICATION FOR A BIOLOGICAL PRODUCT FOR FURTHER MANUFACTURING USE ONLY

☐ AN "IN VITRO" DIAGNOSTIC BIOLOGICAL PRODUCT LICENSED UNDER SECTION 351 OF THE PHS ACT

☐ BOVINE BLOOD PRODUCT FOR TOPICAL APPLICATION LICENSED BEFORE 9/1/92

8. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION? ☐ YES ☐ NO *(See reverse side if answered YES)*

A completed form must be signed and accompany each new drug or biologic product application and each new supplement. If payment is sent by U.S. mail or courier, please include a copy of this completed form with payment.

SIGNATURE OF AUTHORIZED COMPANY REPRESENTATIVE	TITLE	DATE
Bonnie J Goldmann	Bonnie J. Goldmann, M.D. Vice President, Domestic Liaison Regulatory Affairs	2/2/99

Created by Electronic Document Services/USDHHS: (301) 443-2454 EF